TY  - JOUR
AU  - Jackisch, Christian
AU  - Barcenas, Carlos H
AU  - Bartsch, Rupert
AU  - Palma, Jack Di
AU  - Glück, Stefan
AU  - Harbeck, Nadia
AU  - Macedo, Guilherme
AU  - O'Shaughnessy, Joyce
AU  - Pistilli, Barbara
AU  - Ruiz-Borrego, Manuel
AU  - Rugo, Hope S
PY  - 2021
DO  - 10.1016/j.clbc.2021.02.001
UR  - https://hdl.handle.net/10668/27417
T2  - Clinical breast cancer
AB  - Neratinib is an irreversible, pan-human epidermal growth factor inhibitor that has shown efficacy across human epidermal growth factor receptor 2 (HER2)-positive breast cancer settings. Neratinib is indicated for use as extended adjuvant therapy for...
LA  - en
KW  - Breast cancer
KW  - Diarrhea
KW  - HER2
KW  - Metastatic
KW  - Neratinib
KW  - Antimetabolites, Antineoplastic
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Breast Neoplasms
KW  - Capecitabine
KW  - Dose-Response Relationship, Drug
KW  - Female
KW  - Humans
KW  - Neoplasm Metastasis
KW  - Quinolines
KW  - Receptor, ErbB-2
TI  - Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer.
TY  - research article
VL  - 21
ER  -